Printer Friendly

KATHRYN ZOON APPOINTED AS DIRECTOR OF FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

 KATHRYN ZOON APPOINTED AS DIRECTOR OF FDA'S CENTER
 FOR BIOLOGICS EVALUATION AND RESEARCH
 WASHINGTON, March 5 /PRNewswire/ -- Food and Drug Administration Commissioner David A. Kessler, M.D., today announced the appointment of Kathryn C. Zoon, Ph.D., as director of FDA's Center for Biologics Evaluation and Research.
 The center is responsible for ensuring the safety and effectiveness of biological products, such as vaccines, therapeutics and blood products manufactured for interstate sale. It also coordinates FDA's efforts against AIDS, and works to develop an AIDS vaccine and AIDS diagnostic tests.
 "Dr. Zoon's exceptional managerial experience and her outstanding scientific accomplishments will serve her well in this new capacity," Kessler said. "Furthermore, her experience with regulatory and scientific programs will enable her to be a prominent force in the area of biotechnology regulation."
 Gerald V. Quinnan Jr., M.D., who had been acting center director since 1989, will resume the position of deputy director. "Dr. Quinnan's efforts in this position have exemplified his dedication to the job of protecting the public health and promoting good science," Kessler said.
 Zoon has been with CBER since 1980. In 1988 she was named director of the division of cytokine biology, which conducts research on cell biology and cellular and molecular immunology.
 Zoon has been recognized with FDA Awards of Merit for her scientific and managerial accomplishments and for her work on the cytokine review group, for the expeditious review and licensing of AIDS-related cytokine products. She also received the Commissioner's Special Citation Award for exceptional leadership in cytokine biology research and review.
 Zoon has a bachelor of science degree in chemistry from Rensselaer Polytechnic Institute and a doctor of philosophy degree from Johns Hopkins University. She also had a post-doctoral staff fellowship with the National Institutes of Health where she worked with Nobel Laureate Christian B. Anfinsen on one of the first biotechnology-derived products, human interferon alpha.
 -0- 3/5/92
 /NOTE: Attention TV broadcasters: Please use open caption for the hearing impaired./
 /CONTACT: Monica Revelle of the Food and Drug Administration, 301-443-4177 or, after hours, 410-290-6575/ CO: Food and Drug Administration ST: District of Columbia IN: SU: PER


DC-MH -- DC023 -- 5415 03/05/92 11:46 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:363
Previous Article:/A D V A N C E -- FOR RELEASE AT 7 P.M., EST, TODAY/ PRIME DISCOVERY AT AEA TECHNOLOGY'S HARWELL LABORATORY, UK
Next Article:ERI NAMED IBM BUSINESS PARTNER
Topics:


Related Articles
Regeneration Technologies gets FDA's blessing to continue using its BioCleanse process following exchange of letters.
FDA concludes Regeneration Technologies BioCleanse tissue sterilization process needs no regulatory action.
Names in the News.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters